Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
By S. Topalian, Julie R Brahmer, David C. Smith, J. Powderly, Richard D. Carvajal, J. Sosman, Charles G. Drake, Lieping Chen, W. H. Sharfman. New England Journal of Medicine, 2012
11,924 citations recorded by the source corpus.
Background Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. Methods We enrolled patients with advanced melanoma, non–small-cell lung cancer, castration-resistant prostate cancer, or renal-cell or colorectal cancer to receive anti–PD-1 antibody at a dose of 0.1 to 10.0 mg per kilogram of body weight every 2 weeks. Response was assessed after each 8-week treatment cycle. Patients received up to 12 cycles until disease progression or a complete response occurred. Results A total of 296 patients received treatment through February 24, 2012. Grade 3 or 4 drug-related adverse events occurred in 14% of patients; there were three deaths from pulmonary toxicity. No maximum tolerated dose was defined. Adverse events consistent with immune-related causes were observed. Among 236 patients in whom response could be evaluated, objective responses (complete or partial responses) were observed in those with non–small-cell lung cancer, melanoma, or renal-cell cancer. Cumulative response rates (all doses) were 18% among patients with non–small-cell lung cancer (14 of 76 patients), 28% among patients with melanoma (26 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients). Responses were durable; 20 of 31 responses lasted 1 year or more in patients with 1 year or more of follow-up. To assess the role of intratumoral PD-1 ligand (PD-L1) expression in the modulation of the PD-1–PD-L1 pathway, immunohistochemical analysis was performed on pretreatment tumor specimens obtained from 42 patients. Of 17 patients with PD-L1–negative tumors, none had an objective response; 9 of 25 patients (36%) with PD-L1–positive tumors had an objective response (P = 0.006). Conclusions Anti–PD-1 antibody produced objective responses in approximately one in four to one in five patients with non–small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use. Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00730639.)
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/ada133745281f73cc7b8e4043b55844d1ea95de5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- E. Wherry
- Lieping Chen
- D. Pardoll
- James P. Allison
- J. Wolchok
- S. Rosenberg
- Ton N. Schumacher
- G. Freeman
In Oncology
- J. Wolchok
- Lieping Chen
- S. Rosenberg
- James P. Allison
- D. Pardoll
- Ton N. Schumacher
- Antoni Ribas
- E. Wherry
Citations in the corpus
- PD-L1 Expression is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies (2013, positive): “tumors appeared to correlate with treatment response (4).”
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012, neutral): “All squamous type All doses 13 1 8 (0-36) ND 3 23 (5-54) 43 (15-71)”
- Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy (2016, neutral): “…express the PD-1 ligand (PD-L1), and/or contain pre-existing tumor-infiltrating CD8+ T cells that are inhibited locally, e.g., by PD-1 engage- ment (Tumeh et al., 2014; Sharma and Allison, 2015; Rizvi et al., 2015; Schumacher and Schreiber, 2015; Herbst et al., 2014; Topalian et al., 2012, 2015).”
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints (2016, background): “Importantly, (1) elevation of TIM-3 expression in T cells was predominantly found on the therapeutic PD-1 antibody-bound subset, (2) upregulation of TIM-3 was only detected in tumour-bearing lungs but not in sentinel lymph nodes and peripheral blood, (3) TIM-3 positivity was significantly correlated”
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (2017, background): “Inhibitors of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) [8, 9] and of programmed cell death protein 1 (PD-1) receptor [10] were the first drugs of this type, which promote T-cell activation [2].”
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review. (2016, background): “IRAEs are frequent; they occur in up to 90% of patients treated with an anti-CTLA-4 antibody [2] and 70% of patients treated with an PD-1/PD-L1 antibody [11,17].”
- Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 (2018, positive): “Immune checkpoint blockade has emerged as a critical treatment against various cancer types (Topalian et al., 2012).”